Devices Report

Report ID: 2024/002/026/601/060



Administrative information

MHRA 2024-02-26

Type of Report Reference assigned by the manufacturer

Initial FSN 001/24

2024/002/026/601/060 -

Name of the co-ordinating NCA Competent Authority (if applicable)

_

Information on the submitter of the report

Submitter of report

Manufacturer

Manufacturer information

Manufacturer Organisation name Contact Name

HMC Premedical spa Emanuela Govi

E-mail Phone

emanuela.govi@hmcgroup.it +39053522704

CountryAddressItalyVia Bosco 1/3

City namePostcodeMirandola41037

Authorized representative information

Authorised representative Organisation name

HMC Medical UK Limited

E-mail

info@hmcmedical.co.uk

Country

United Kingdom

City Blackrod, Bolton Joanne 30

Contact NameJoanne Schmidt

Phone

+441204695050

Address

Unit 2 Rivington View Business Park

Postcode

BL6 5BN

National Contact Point Information

National contact point organisation name

HMC Medical UK Limited

E-mail

info@hmcmedical.co.uk

Country

GB

City name Blackrod, Bolton Name of the contact person

Joanne Schmidt

Phone

+441204695050

Address

Unit 2 Rivington View Business Park

Postcode BL6 5BN

Medical Device Information

Class

MDD Class IIb

Medical device nomenclature code

64616

Commercial name/brand name/make

ENFit double-lumen polyurethane "Replogle" tube

Catalogue/Reference number

NF02L

Lot/batch number(s)

19109004 21F18002 23C03045 23C03046

Device expiry date

-

Details of additional devices/ accessories

involved in the incident

Nomenclature system (preferable GMDN)

GMDN

Nomenclature text

ENFit double-lumen polyurethane "Replogle" tube

Model

NF02L

Serial number(s)

-

Device manufacturing date

-

Notified body (NB) ID number(s) (if applicable

•

Software version (if applicable)

-

Description of FSCA

Background information and reason for the FSCA

The hospital reported that there was a problem with location of the irrigation holes in the ENFit 10fr double Lumen Replogle Tube with a neonate patient. When the tube was in situ in the patient, and saline was administered for irrigation, the saline came out of the first hole in the tube, which is (roughly) 7cm from the end of the tube . The patient that required the tube has an oesophageal atresia 9.5cm down from her mouth meaning that the tube was only inserted to 9.5cm. The result was that the saline came out (roughly) 3cm away from her mouth which was likely above the epiglottis and a huge risk of aspiration. This also meant that the patient secretions were not loosened and blocked the suction holes.

Advice on actions to be taken by the distributor and the user

Users should contact Medicina who will arrange collection and destruction of the batches specified.

Time schedule for the implementation of the different actions

Subject to approval of draft FSCA by MHRA, notifications to all customers in territory can be sent within 5 working days of approval, follow-up every 7 working days thereafter

FSN status

Final FSN

All EEA, Great Britain, candidate countries and Switzerland

_

Other Countries (including Northern Ireland)

_

Description and justification of the action (corrective / preventive)

The defective sample is not available for investigation. Since the device was put on the market, we have never received similar complaint. From the feedback received from the hospital, the appropriate procedure was followed for the use of the device. The reporter identified a difference in the position of the holes in the device, compared with the competitor device (Cardinal Health Replogle Tube). The position of the holes on the competitor device is closer to the end of the tube the first hole being roughly 2cm from the end of the tube. We cannot eliminate the possibility that the location of the holes on the tube contributed to the complications experienced by the patient. Without access to the tubes subject to the complaint but based on the available information from the reporter it is not possible to exclude the possibility that the design of this device resulted in the complications the patient experienced. For this reason, the decision has been taken to initiate a recall. The product will be placed in quarantine, and the recall notice will be issued. The product will be withdrawn from the market and no new batches of the product will be placed on the market.

Progress of FSCA, together with reconciliation data

_

Attached Please Find

Field Safety Notice (FSN) in English

Attachments

File Name FSN 001/24

Distribution (Multiple choice)

-

Comments

Comments

Incident also reported MHRA code 2024/002/026/601/052.